Research programme: vaginal infection antimicrobial peptides - C3J Therapeutics

Drug Profile

Research programme: vaginal infection antimicrobial peptides - C3J Therapeutics

Latest Information Update: 18 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator C3 Jian
  • Developer C3J Therapeutics
  • Class Peptide fragments
  • Mechanism of Action Peptide stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Candidiasis; Vaginitis

Most Recent Events

  • 18 Apr 2018 Discontinued - Preclinical for Candidiasis in USA (unspecified route) (C3J Therapeutics pipeline, April 2018)
  • 18 Apr 2018 Discontinued - Preclinical for Vaginitis in USA (unspecified route) (C3J Therapeutics pipeline, April 2018)
  • 29 Nov 2016 C3 Jian is now called C3J Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top